Latest Announcements

BSE & NSE corporate filings with AI summaries

BSEBoard MeetingResults28 Oct 2026

Integra Essentia Ltd

Integra Essentia Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2026 ,inter alia, to consider and approve Intimation of Board Meeting to be held on Saturday, October 31, 2026

Integra Essentia Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 31/10/2026 to consider and approve unaudited financial results for the quarter and half year ended September 30, 2026.

Read more →📎 1 attachment
BSEBoard MeetingResults28 Oct 2026

Global Vectra Helicorp Ltd

Global Vectra Helicorp Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve Pursuant to Regulaiton 29(I) (a) read with Regulation 46 (2) (I) (i) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that a Meeting of the Board of Directors of the Company to be held on Friday , 06th November, 2026 at the Corporate Office ....

Global Vectra Helicorp Ltd has scheduled a board meeting on 06/11/2026 to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026.

Read more →📎 1 attachment
NSEOutcome of Board MeetingResults28 Oct 2026

GRP Limited

Outcome of Board Meeting

GRP Limited has submitted its unaudited financial results for the quarter and half year ended September 30, 2026, and noted changes in the constitution of internal auditors and SOP fines imposed by stock exchanges.

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults28 Oct 2026

Himadri Speciality Chemical Ltd

Transcript of Earnings Conference Call for Financial Performance for the 2nd Quarter and half year ended 30 September 2026

Himadri Speciality Chemical Ltd has announced its Q2 FY27 earnings, with revenue surpassing INR 3,000 crores, EBITDA exceeding INR 600 crores, and profit after tax crossing INR 450 crores. The company has made significant progress in its transformation journey, with various initiatives translating from research to commercialisation. Key highlights include the development of differentiated technologies, validation with customers, and scaling in a disciplined manner across speciality and advanced materials.

Read more →📎 1 attachment
BSEBoard MeetingResults28 Oct 2026

Ion Exchange India Ltd-$

Ion Exchange India Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Unaudited Financial Results for the second quarter and half year ended September 30, 2026.

Ion Exchange India Ltd has scheduled a Board Meeting on November 3, 2026, to consider and approve the Unaudited Financial Results for the second quarter and half year ended September 30, 2026.

Read more →📎 1 attachment
BSECompany UpdateResults28 Oct 2026

Onesource Specialty Pharma Ltd

Intimation about publication of newspaper advertisement - Extract of unaudited Standalone and Consolidated financial results for the quarter and half year ended September 30, 2026.

Onesource Specialty Pharma Ltd has published a newspaper advertisement announcing the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Read more →📎 1 attachment
BSEBoard MeetingResults28 Oct 2026

PDS Ltd

PDS Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve 1.The Un-audited Standalone and Consolidated Financial Results of the Company for the quarter & half year ended on September 30, 2026; 2.Declaration of Interim Dividend for the financial year 2026-27, if any; and 3.Any other matter with the permission of the Chair.

PDS Ltd has scheduled a Board Meeting on November 4, 2026, to consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, and to declare an interim dividend for the financial year 2026-27, if any.

Read more →📎 1 attachment
BSEBoard MeetingResults28 Oct 2026

Sanofi Consumer Healthcare India Ltd

We wish to inform you that the Board of Directors at its meeting held today, i.e. Wednesday, 28th October 2026, inter alia considered and approved the Unaudited Financial Results for the quarter and nine months ended 30th September 2026.

Sanofi Consumer Healthcare India Ltd has announced its unaudited financial results for the quarter and nine months ended 30th September 2026, which were approved by the Board of Directors at its meeting held on 28th October 2026.

Read more →📎 1 attachment
BSEBoard MeetingResults28 Oct 2026

Rajvi Logitrade Ltd

Rajvi Logitrade Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Un-audited Financial Results of the company alongwith limited review report for the Quarter and Half year ended on 30th September 2026.

Rajvi Logitrade Ltd has scheduled a Board Meeting on 05/11/2026 to consider and approve Un-audited Financial Results for the Quarter and Half year ended on 30th September 2026.

Read more →📎 1 attachment
BSECompany UpdateResults28 Oct 2026

Emkay Global Financial Services Ltd

Statement of Material Deviation in case of preferential issue

Emkay Global Financial Services Ltd has announced the outcome of its Board Meeting held on 28 October 2026, where the Board approved the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. The company has also disclosed the utilization of issue proceeds of Non-Convertible Debentures and Material Deviation(s) pursuant to SEBI Listing Regulations.

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults28 Oct 2026

PNC Infratech Ltd

as per attachment

PNC Infratech Limited announces unaudited financial results for Q2 and H1 FY'27, with standalone revenue of Rs. 1146 Cr., EBITDA of Rs. 138 Cr., and PAT of Rs. 73 Cr. for Q2, and H1 revenue of Rs. 2664 Cr., EBITDA of Rs. 513 Cr., and PAT of Rs. 343 Cr. Consolidated revenue and EBITDA also show significant growth.

Read more →📎 1 attachment
← PreviousPage 1307 of 4533Next →